Is ICON Public Limited Company (ICLR) a Buy, Sell, or Hold?
ICON Public Limited Company
NASDAQ:ICLR
$172.08 USD
$4.11 (2.45%)
- Volume
- 454.81K
- Average Volume
- 1.21M
- Market Capitalization
- $13.18B
- P/E Ratio
- 30.40
- Dividend Yield
- 0.00%
- Price Target
- $170.00
- Year High
- $211.00
- Year Low
- $66.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.14
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Barry Balfe |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | ICLR |
| CUSIP | G4705A100 |
| CIK | 0001060955 |
| Web | https://www.iconplc.com |
| Phone | 353 1 291 2000 |
| Currency | USD |
| Employees | 40100 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | 0.38 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.14 |
| Quick Ratio | 1.14 |
| Cash Ratio | 0.24 |
Sales & Book Value
| Annual Sales | $8.25B |
| Price / Sales | 1.61 |
| Cash Flow | 16.17 |
| Price / Cash Flow | 10.64 |
| Price / Book | 1.42 |
Price Target and Rating
| Average Stock Price Forecast | $170.00 |
| High Stock Price Forecast | $207.00 |
| Low Stock Price Forecast | $100.00 |
| Forecast Upside/Downside | 1.22% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 30 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.9 |
| Trailing P/E Ratio | 30.40 |
| PEG Ratio | -0.78 |
| P/E Growth | -0.78 |
| Net Income | $229.34M |
| Net Margin | 5.35% |
| Pretax Margin | 5.93% |
| Return on Equity | 4.70% |
| Return on Assets | 2.69% |
Financials Score
| AltmanZ Score | 1.96 |
| Piotroski Score | 7.00 |
| Working Capital | 437.8M |
| Total Assets | 16.32B |
| Ebit | 686.56M |
| Market Cap | 12.86B |
| Total Liabilities | 7.02B |
Poll Results
About ICON Public Limited Company (NASDAQ:ICLR) Stock
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition ... , the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline
2026-07-15 11:01:10
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm
2026-07-09 16:51:00
NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating: ICON plc (NASDAQ: ICLR) shareholders should email [email protected] What is the Investigation About ? On February 12, 2026, ICON issued a press release entitled "ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices.
RESERVOIR ANNOUNCES PUBLISHING DEAL WITH MULTI-PLATINUM AND GRAMMY-WINNING HIP-HOP ICON T.I.
2026-07-09 08:00:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Reservoir Media, Inc. (NASDAQ: RSVR, the "Company"), an award-winning independent music company, today announced a publishing deal with hip-hop icon T.I. Under the agreement, Reservoir will work alongside T.I.
ICON Stock and the CRO Trends Shaping Its Next Growth Phase
2026-07-08 15:10:19
ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset?
2026-07-07 13:25:53
ICON trades below its five-year median, but weaker 2026 guidance, control issues and leverage keep the stock in wait-and-see territory.
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base
2026-07-06 15:36:13
ICON's stronger bookings and backlog hint at improving demand, but margin pressure, earnings declines and control remediation keep 2026 cautious.
ICON Q1 2026: Margins Face Questions, But The Long-Term Thesis Holds
2026-06-25 06:09:21
ICON plc delivered a modest 1Q26 beat, with EPS of $2.50 and revenue of $2.03B, but growth was subdued and margins compressed. ICLR reaffirmed FY26 guidance—revenue of $7.85–$8.15B and EPS of $10–$11—signaling management confidence in a back-half recovery. Profitability faced pressure as adjusted EBITDA fell over 20% and margins dropped to 15.6%, driven by business mix and integration costs.
Why Icon Stock Crushed it on Wednesday
2026-06-24 17:02:33
It posted mixed results, but investors looked past this to other encouraging developments. In particular, this included gross bookings for the period.
Frequently Asked Questions
-
What is the current ICON Public Limited Company (ICLR) stock price?
-
ICON Public Limited Company(NASDAQ:ICLR) stock price is $172.08 in the last trading session. During the trading session, ICLR stock reached the peak price of $211 while $66.57 was the lowest point it dropped to. The percentage change in ICLR stock occurred in the recent session was 2.45% while the dollar amount for the price change in ICLR stock was $4.11.
-
ICLR's industry and sector of operation?
-
The NASDAQ listed ICLR is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of ICLR?
-
Lyons Emer | Chief Accounting Officer
John Climax | Founder & Independent Non-Executive Director
Barry Balfe | Chief Executive Officer & Director
David Green | Vice President of Marketing
Diarmaid Cunningham | Chief Administrative Officer, General Counsel & Company Secretary -
How many employees does ICLR have?
-
Number of ICLR employees currently stands at 40100. ICLR operates from South County Business Park, Dublin, DU D18 X5R3, IE.
-
Link for ICLR official website?
-
Official Website of ICLR is: https://www.iconplc.com
-
How do I contact ICLR?
-
ICLR could be contacted at phone #353 1 291 2000 and can also be accessed through its website. ICLR operates from South County Business Park, Dublin, DU D18 X5R3, IE.
-
How many shares of ICLR are traded daily?
-
The average number of ICLR shares traded daily for last 3 months was 1.21M.
-
What is the market cap of ICLR currently?
-
The market value of ICLR currently stands at $13.18B with its latest stock price at $172.08